Figure 1

Effects of treatments on HT-29 and K562 cells viability and cell cycle. Apoptosis and necrosis were estimated after treatment. HT29-pNF-κB-hrGFP reporter cells HT29 (Fig A) and immortalized myelogenous leukemia cells from human K562 (Fig B) and were treated with M1, M2 and M8 and percentage of cell death was determined by flow cytometry. Annexin V-FITC Apoptosis detection kit (BIOPharmigen) and propidium iodide (PI) were used to evaluate cell viability and DNA content in cell cycle. ANOVA and Tukey test were use to determine statistical differences. Neither highly diluted compound were cytotoxic nor have effects on cell cycle. *p < 0.05